RESEARCH ARTICLE

Endometrial Curettage in Abnormal Uterine Bleeding and Efficacy of Progestins for Control in Cases of Hyperplasia

Simender Mesenci-Haftaci1*, Handan Ankarali2, Ali Yavuzcan3, Mete Caglar3

Abstract

Background: Abnormal uterine bleeding (AUB) is the most important symptom of endometrial hyperplasia and endometrial curettage (EC) is the gold standard diagnostic procedure. We present the results of patients who underwent EC for AUB and the efficacy of progestin administration in those with endometrial hyperplasia.

Materials and Methods: A total of 415 female patients who presented to Duzce Public Hospital in 2011-2012 for AUB and who underwent EC were included. We determined the reasons for AUB, and females with hyperplasia were treated with 10 mg/day medroxyprogesterone acetate for 14 days/month or 160 mg/day megestrol acetate continuously for 3 months. We evaluated the efficacy of progestins for periods of three and/or six cycles by repeating EC. A statistical analysis of specific endometrial causes according to age of presentation was conducted using the chi-square test.

Results: Among the 415 females (average age, 53.5 years) followed for 6 months, 186 had physiological changes (44.8%), 89 had simple hyperplasia (21.4%), 1 had atypical hyperplasia (0.2%), 6 had complex hyperplasia (1.4%), 3 had atypical complex hyperplasia (0.7%), and 5 had adenocarcinoma (1.2%). Regression rates were 72.7-100%, and the optimum results were observed after 6 months of hormonal therapy.

Conclusions: The main cause of AUB was physiological change. Progestin therapy resulted in significant regression even in females with atypical hyperplasia.

Keywords: Abnormal uterine bleeding - endometrial curettage - endometrial hyperplasia - MPA - megestrol acetate
duration, administration route, or the most effective type of progestin (Ferenczy et al., 1989; Tasci et al., 2014). No evidence from randomized controlled trials is available, and no randomized controlled trials on the efficacy of progestin treatment in terms of achieving a pathologically complete response are currently underway (Baker et al., 2012).

Although hysteroscopic evaluation is the gold standard for AUB, endometrial curettage (EC) continues to be performed in public hospitals. Endometrial sampling is a preferred procedure for diagnosis of the endometrial pathology (Balik et al., 2013); and EC (with conventional dilatation and curettage) is a valuable and cost-effective technique for evaluation of intrauterine pathologies that clearly demonstrates the hormonal response of the endometrium and provides beneficial information regarding atrophy, infections, or other lesions (Sarwar et al., 2005). In this study, the histopathological results of EC in females aged 21-86 years who had AUB were collected from our outpatient clinic without regard to menopausal status. We also investigated the efficacy of progestins (MPA and megestrol acetate) for 3 and/or 6 months in patients with endometrial hyperplasia.

Materials and Methods

Subjects

Our study included 415 females (mean age, 53.5±8.53 years; range 21-86 years) who underwent EC for AUB during from October 2011 to December 2012 at Duzce Public Hospital, Duzce, Turkey. This study protocol was approved by the Ethics Committee of Duzce University, and written informed consent was obtained from all subjects.

Subjects with isolated endometrial causes of AUB were included, and those with fibroids, cervical, and vaginal and hemostatic disorders were excluded. EC was performed in the late luteal phase under general anesthesia by conventional dilatation and curettage. All specimens were transported to the pathology laboratory in 10% formalin and stained with hematoxylin and eosin. Histopathological results were evaluated, and patients with hyperplasia were identified. Patients with simple hyperplasia were given 10 mg/d MPA orally (Tarfulasal™, Deva,Turkey), 14 days per month for 3 months. Patients with atypia who declined surgery or who were medically unfit to undergo surgery were given 1 mg/d megestrol acetate (MA) orally (Megace™, Bristol-Meyers Squibb, New York, NY, USA) continuously for 3 months. MA treatment. The feedback rate for the first control EC from our control group was 80%. The patient with hyperplasia and atypia was operated on and excluded from the group. Two of the three females with CAH provided feedback. Benign findings were seen in both of the patients at the first control after MA treatment. The feedback rate for the first control EC after progestin in all hyperplasia groups was 67% (Table 2).

Statistical analysis

Data are presented as means±standard deviations or as frequencies (percentages). One-way analysis of variance was used to compare the pathology results according to age. Categorical variables were assessed using Pearson’s chi-square test. A p≤0.05 was considered to indicate significance. The PASW ver. 18 (SPSS, Inc., Chicago, IL, USA) software was used for the statistical analysis.

Results

The most common finding in the 415 patients with AUB was benign physiological changes (44.8%). Other results were polyps (30%), SH (21.44%), CH (1.44%), adenocarcinoma (1.2%), CAH (0.72%) and AH (0.2%). The pathology results differed significantly according to age and menopausal status (p=0.008 and 0.002, respectively; Table 1).

Sixty-nine patients with SH of the eighty-nine administered MPA gave feedback regarding control of EC. After the first 3 months of treatment, hyperplasia persisted in 19.7%. The regression rate to benign findings was 77.1%; atypia and progression to CH occurred in 3.2% of the patients. Five patients with CH of the six administered MPA gave feedback regarding control of EC. There was no persistence but one progression. Regression rate was 80%. The patient with hyperplasia and atypia was operated on and removed from the group. Two of the three females with CAH provided feedback. Benign findings were seen in both of the patients at the first control after MA treatment. The feedback rate for the first control EC after progestin in all hyperplasia groups was 67% (Table 2).

Table 1. Pathology Results of First Endometrial Curettage, Menopausal Status, and Mean Age

| Diagnosis                | Histology Results | No* (%) | Menopausal status** | Mean age |
|--------------------------|-------------------|---------|---------------------|----------|
| Benign                   |                   | 186     | M+ (50)             | 47.3 (±11.4) |
| Simple hyperplasia       |                   | 89      | M+ (7)              | 44.4 (±7.6)  |
| Complex hyperplasia      |                   | 6       | M+ (2)              | 50 (±5.2)   |
| Atypical hyperplasia     |                   | 1       | M+ (1)              | 52         |
| Complex-atypical hyperplasia |         | 3      | M+ (1)              | 38 (±14.9)  |
| Cancer                   |                   | 5       | M+ (3)              | 55.6 (±8.5) |
| Polyps                   |                   | 125     | M+ (23)             | 44.4 (±8.9) |

*Number of patients; **M+, postmenopausal period

Table 2. Efficacy of 3 Months of Progestin Therapy

| Diagnosis                | Follow up* | Regression | Persistence | Progression |
|--------------------------|------------|------------|-------------|-------------|
| Simple hyperplasia       | 89         | 61 (68.5)  | 77          | 19.70       | 3.20        |
| Complex hyperplasia      | 6          | 5 (83.3)   | 80          | 0           | 20          |
| Atypical hyperplasia     | 1          | 0 (0)**    | 100         | 0           | 0           |
| Atypical complex hyperplasia | 3      | 2 (66.6)   | 100         | 0           | 0           |

*All patients with endometrial hyperplasia were called for control EC after 3 months of progestin therapy, but not all patients attended the control; **This patient was operated on and excluded from the control group
Efficacy of 6 Months of Progestin Therapy

| Diagnosis                        | No. of patient | Follow up* | Regression | Persistence | Progression |
|----------------------------------|----------------|------------|------------|-------------|-------------|
| Simple hyperplasia               | 12             | 11 (91.6)  | 8 (72.7)   | 3 (27.3)    | 0 (0)       |
| Complex hyperplasia              | 1              | 1 (100)    | 1 (100)    | 0 (0)       | 0 (0)       |
| Atypical hyperplasia             | 1              | 0 (0)**    | 1 (100)    | 0 (0)       | 0 (0)       |
| Atypical complex hyperplasia     | 2              | 1 (50)     | 1 (100)    | 0 (0)       | 0 (0)       |

*Patients who returned for the third endometrial curettage; **Excluded from the control group

The proportion of patients who attended the third EC after 6 months of therapy was 85%. Regression rates were 72.7%, 100%, and 100% for SH, CH, and CAH. No persistence or progression was observed in patients with CH and CAH, but 27.3% of patients with SH exhibited persistence (Table 3).

Discussion

Few studies of AUB have included all ages, because age-related causes are important from an oncological perspective. The majority of our patients had benign findings (44.8%), followed by polyps (30%), endometrial hyperplasia (24%) and adenocarcinoma (1.2%). The proportions of polyps and hyperplasia in EC specimens were greater than those reported previously (Montgomery et al., 2004; Espindola et al., 2007). In a similar study including patients of all ages, benign findings included disordered proliferation (93.4%), polyps (3.9%), hyperplasia (2.5%), and malignancy (0.7%) (Soleymani et al., 2013). When we evaluated the responses to progestin, our regression rates were 77.1% for SH; 80% for CH, and 100% for CAH after 3 months of hormone therapy. We had a limited number of hyperplasia cases (89 cases). Our regression rates after 6 months of hormone therapy were 72.7%, 100%, and 100% for SH, CH, and CAH, respectively. Our persistence and progression rates were 22.9% for SH, 20% for CH, and 0% for CAH after 3 months of therapy, and we identified no persistence or progression in patients after 6 months of therapy.

The SH regression rate has been reported to be 74-80%, with a 1% progression rate (Tabata et al., 2001; Montgomery et al., 2004). In a recent study, complete resolution was found in 72% of 60 cases after 3 months of progestin therapy, with no progression (Tasci et al., 2014). Most studies have focused on only SH or CAH. In a similar study of 31 females aged 30-70 years with endometrial hyperplasia, persistence was evident in 45% following MPA therapy; this was the highest rate reported in the literature. However, all endometrial hyperplasia types were evaluated, as in our study, which might explain the high rate of persistence (Vereide et al., 2003).

Orbo et al. reported that 54% of patients receiving oral MPA (10 mg/day, 10 days) showed responses, whereas spontaneous regression was seen in 50% of the cases after 6 months (Orbo et al., 2008). In contrast, Tabata et al. observed spontaneous regression of endometrioid hyperplasia in all risk groups, and the overall regression rates were 79% for SH, 100% for AH, 94% for CH, and 55% for CAH; regression occurred mostly within the first year (Tabata et al., 2001). Clearly, results were improved with a follow-up of longer duration. In a similar study, the regression rates were 96.66% and 3.3% for SH and AH, respectively (Ismail et al., 2013).

In a recent cohort study, the likelihood of histological persistence/progression of CH and AH among females treated with a progestin compared with those not treated was investigated. Females with CAH who received MA had a 69% decreased risk of persistence/progression compared with those who did not receive progestin, and those who received MPA had a 49% decreased risk of persistence/progression (Reed et al., 2009). Those authors concluded that there were no differences in endometrial hyperplasia regression rates in females administered various oral progestogens. Ozdeginemci et al. reported that the rate of resolution of endometrial hyperplasia without atypia was 96.7% and that of persistence was 3.3% (Ozdeginemci et al., 2011). Ferenczy and Gelfand used the same MPA protocol as our study and reported a persistence rate of 14% in females without cytological atypia (Ferencywicz et al., 1989). We also concluded that most studies of MPA efficacy are based on the results of a 10 days/month protocol.

Another study examined the likelihood of regression of endometrial hyperplasia in relation to progestin therapy. In that study, females with CH without atypia were treated with norethisterone acetate and MPA (10-20 mg/day) for 3-5 months, and a second biopsy was performed. Regression was evident in 61.5% of the patients (Horn et al., 2004). Approximately 60-70% of cases of CH have been reported to respond to progestin treatment (Wang et al., 2003). According to a meta-analysis of nine studies (n=213) of females with SH treated with oral progestins, the regression rate was 89% in 389 females with CH; and in 14 studies with 189 females with AH the regression rate was 69% (Gallos et al., 2010). In a study that had the longest follow-up duration to date, 81 females with CH exhibited regression and persistence rates of 90% and 0.9% respectively. The median duration of follow up was 95.1 months. According to previous studies, the risk of progression or persistence is 0-60% for CH and 10-100% for AH following progestin therapy (Ferency et al., 1989; Randall et al., 1997; Horn et al., 2004).

The levonorgestrel-releasing intrauterine system, which has been advocated in many studies, has been found to be superior to oral progestins. However, no randomized studies of the efficacy of all types of oral progestins with an at least 5-year follow-up have been conducted (Gallos et al., 2010; 2012; 2013a; 2013b). The duration and type of progestin therapy, and the optimal biopsy time, remain controversial in females with endometrial hyperplasia. A follow-up biopsy at 3 months following the initial treatment has been suggested as it corresponds to the average response time. A lack of response at the first biopsy (8-12 weeks after initiating treatment) suggests treatment failure (Simpson et al., 2014).

Ca. 60% of females with CAH had concurrent endometrial carcinoma, which is similar to recent reports (Robbe et al., 2012). Therefore, each patient should be evaluated individually and be informed of the risks of medical therapy.
References

Acmaiz G, Aksoy H, Unal D, et al (2014). Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding? Asian Pac J Cancer Prev, 15, 1689-92.

ACOG Practice Bulletin No. 128 (2012). Diagnosis of abnormal uterine bleeding in reproductive-aged women. Committee on Practice Bulletins-Gynecology. Obstet Gynecol, 120, 197-206.

Baker J, Obermair A, Gebski V, Janda M (2012). Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. Gynecol Oncol, 125, 263-70.

Balik G, Kapici G, Ustuner I, Akpinar F, Gulevendag Guven ES (2013). Which endometrial pathologies need intraoperative frozen sections? Asian Pac J Cancer Prev, 14, 6121-5.

Eppler M, Reed SD, Voigt LF, et al (2008). Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol, 168, 563-70.

Espindola D, Kennedy KA, Fischer EG (2007). Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia. Obstet Gynecol Clin North Am, 34, 717-37.

Ferenczy A, Gelfand M (1989). The biologic and significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol, 160, 126-31.

Gallos ID, Shehmar M, Thanqaratim S, et al (2010). Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol, 203, 547, 1-10.

Gallos ID, Devey J, Ganesan R, Gupta JK (2013). Predictive ability of estrogen receptor(ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study. Gynecol Oncol, 130, 58-63.

Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK (2013). Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long term follow up. Hum Reprod, 28, 1231-3.

Gallos ID, Yap J, Rajkhowa M, et al (2012). Regression, relapse, and live birth rates with fertility sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol, 207, 266, 1-12.

Horn LC, Schwurmnbusch U, Bilek K, Hentschel B, Einenkel J (2004). Risk of progression in complex and simple endometrial hyperplasia: clinicopathologic analysis in cases with and without progesterone treatment. Int J Gynecol Cancer, 14, 348-53.

Ismail MT, Fahmy DM, Elshmaa NS (2013). Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia. Reprod Sci, 20, 45-50.

Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, et al (2010). Clinical practice guidelines on menorrhagia:management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol, 152, 133-7.

Montgomery BE, Daum GS, Dunton CJ (2004). Endometrial hyperplasia: a review. Obstet Gynecol Surv, 59, 368-78.

 Munro MG, Critchley HO, Broder MS, Fraser IS (2011). FIGO classification system(PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. FIGO Working Group on Menstrual Disorders. Int J Gynaecol Obstet, 113, 3-13.

Orbo A, Arnes M, Hancke C, et al (2008). Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol, 111, 68-73.

Ozdegermenci O, Kaycioglu F, Bozkurt U, Akgul MA, Haberal A (2011). Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Gynecol Obstet Invest, 72, 10-4.

Randall TC, Kurman RJ (1997). Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol, 90, 434-40.

Reed SD, Voight LF, Newton KM, et al (2009). Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol, 113, 655-62.

Robbe EJ, van Kuijck SM, de Boed EM, et al (2012). Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. Int J Gynecol Cancer, 22, 264-72.

Sarwar A, ul Haque A (2005). Types and frequencies of pathologies in endometrial curettages of abnormal uterine bleeding. Int Pathol, 3, 65-70.

Simpson AN, Feigenberg T, Clarke BA, et al (2014). Fertility sparing treatment of complex endometrial hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol, 133, 229-33.

Soleymani E, Ziai K, Rahmani O, et al (2013). Histopathological findings of endometrial specimens in abnormal uterine bleeding. Arch Gynecol Obstet, 8, 10.

Tabata T, Yamawaki T, Yabana T, et al (2001). Natural history of endometrial hyperplasia. Study of 77 patients. Arch Gynecol Obstet, 265, 85-8.

Tasci Y, Polat OG, Ozdogan S, et al (2014). Comparison of the efficacy of micronized progestrone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch Gynecol Obstet, 2, 1.

Turan T, Karadag B, Karabuk E, et al (2012). Accuracy of frozen sections for intraoperative diagnosis of complex atypical endometrial hyperplasia. Asian Pac J Cancer Prev, 13, 1953-6.

Wang S, Padney J, Song J, et al (2003). Mechanism involved in the evolution of progestin resistance in human endometrial hyperplasia - precursor of endometrial cancer. Gynecol Oncol, 88, 108-17.

Vercide AB, Arnes M, Straume B, Maltau JM, Orbo A (2003). Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol, 91, 526-33.